In this report we evaluated the anti-tumor activity of concurrent α-TEA and anti-HER2/neu antibody treatment against HER2/neu-expressing murine mammary and human breast cancer cells in vitro and on established HER2/neu+ human breast cancer in a murine xenograft tumor model. This evidence concerns the gene ERBB2 and breast carcinoma.